Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
ADC ID |
DRG0VYACH
|
|||||
---|---|---|---|---|---|---|
ADC Name |
CBX-12
|
|||||
Synonyms |
CBX 12; CBX12
Click to Show/Hide
|
|||||
Organization |
Cybrexa, Inc.
|
|||||
Drug Status |
Phase 1/2
|
|||||
Indication |
In total 2 Indication(s)
Phase 2
Phase 2
|
|||||
Antibody Name |
Undisclosed
|
Antigen Name |
Undisclosed
|
|||
Payload Name |
Exatecan
|
Payload Info | ||||
Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
Linker Name |
Undisclosed
|
|||||
Combination Type |
Alphale-exatecan
|
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 9.96% (Day 23) | |||
Method Description |
Ceralasertib=25 mg/kg.
|
||||
In Vivo Model | Colon cancer CDX model | ||||
In Vitro Model | Colon cancer | HCT 116 cells | CVCL_0291 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 42.76% (Day 35) | |||
Method Description |
Ceralasertib=25 mg/kg.
|
||||
In Vivo Model | Breast cancer CDX model | ||||
In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 56.70% (Day 23) | |||
Method Description |
CBX-12=5 mg/kg.
|
||||
In Vivo Model | Colon cancer CDX model | ||||
In Vitro Model | Colon cancer | Colon cancer cells | Homo sapiens | ||
Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 76.32% (Day 35) | |||
Method Description |
CBX-12=10 mg/kg.
|
||||
In Vivo Model | Breast cancer CDX model | ||||
In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 81.22% (Day 23) | |||
Method Description |
Ceralasertib=25 mg/kg + CBX-12=5 mg/kg.
|
||||
In Vivo Model | Colon cancer CDX model | ||||
In Vitro Model | Colon cancer | Colon cancer cells | Homo sapiens | ||
Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 95.40% (Day 35) | |||
Method Description |
Ceralasertib=25 mg/kg + CBX-12=10 mg/kg.
|
||||
In Vivo Model | Breast cancer CDX model | ||||
In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.